Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Heparin Prescribers for ACS (US)

Analysis of: Medtronic Endeavor Heart Stent Tied to Complications (www.bloomberg.com)
The Endeavour stent appears to have a higher restenosis rate than currently marketed Drug Eluting Stents without the improved safety profile claimed by the company.  This finding is at odds with the companies marketing message to cardiologists.  These studies, along with the introduction of...
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone (www.novartis.com)
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
Analysis of: Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration (www.pipelinereview.com)
TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin.  Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....
Analysis of: Schering releases ENHANCE data today (www.tradingmarkets.com)
Physicians have several possible conclusions that can be taken; These include: - the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study -  the failure to meet the trial endpoint is only a surrogate and clinical trial data...
Analysis of: Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data (pharmalive.com)
Exforge (valsartan/amlodipine) is likely to be well received by physicians who have been fond of Lotrel and prefer branded hypertensive therapies to generic agents.
Analysis of: Consumer Outreach Boosts Generic Cholesterol-Fighting Drugs (www.pharmalive.com)
This article summarizes the DTC strategies used to encourage generic utilization for prescription therapies, changing the dynamic from the perception that these therapies are inferior but acceptable alternatives to branded therapies to the impression that these are superior from a consumer value st...
Analysis of: Abbott Announces FDA Approval of a New Coated Niaspan Tablet (pharmalive.com)
Much attention has been brought to HDL, its metabolism and potential for risk modification with HDL raising therapies.  With the demise of the CETP inhibitor torcetrapib (ILLUMINATE and ILLUSTRATE NEJM 2007; 356:1304-1316) and the ACAT inhibitor pactimibe in the ACTIVATE study (NEJM 354:1253-1263)...
Analysis of: UNLOAD Raises Questions About How Ultrafiltration, Diuretics Work in Acute Heart Failure (www.medscape.com)
UNLOAD has provided additional information about the potential utility for ultrafiltration in the management of acutely decompensated patients with CHF admitted to the hospital for volume unloading routinely performed with IV diuretics.Although safety and efficacy may be superior to diuretic based regimens...

Page : 11 to 8 of 8

Analytics


Generated at 2009-01-07T13:00:17.563